Judy Zhong (Hua Zhong)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Advanced Cancer

Randomized Controlled Trial

Glycemic Control

Electronic Health Record

Top Venues

Journal of the American Medical Informatics Association : JAMIA

Journal of the American Geriatrics Society

This page only lists publications with an associated author ORCID identifier.

Publications

Jiyu Kim, Rebecca Anthopolos, Judy Zhong
Bias correction models for electronic health records data in the presence of non-random sampling. Biometrics 80 (1) (2024)
Bo Young Kim, Rebecca Anthopolos, Hyungrok Do, Judy Zhong
Model-based estimation of individual-level social determinants of health and its applications in All of Us. Journal of the American Medical Informatics Association : JAMIA (2024)
Bo Young Kim, Rebecca Anthopolos, Hyungrok Do, Judy Zhong
Model-based estimation of individual-level social determinants of health and its applications in All of Us. Journal of the American Medical Informatics Association : JAMIA (2024)
Jiyu Kim, Rebecca Anthopolos, Judy Zhong
Bias correction models for electronic health records data in the presence of non-random sampling. Biometrics 80 (1) (2024)
Milla E Arabadjian, Zoe T Duberstein, Sarah H Sperber, Kiranjot Kaur, Jolaade Kalinowski, Yuhe Xia, Anaïs Hausvater, Olivia O'Hare, Nathaniel R Smilowitz, Victoria Vaughan Dickson, Judy Zhong, Jeffrey S Berger, Judith S Hochman, Harmony R Reynolds, Tanya M Spruill
Role of Resilience in the Psychological Recovery of Women With Acute Myocardial Infarction. Journal of the American Heart Association (2023)
Jeannette M Beasley, Emily A Johnston, Denisa Costea, Mary Ann Sevick, Erin S Rogers, Melanie Jay, Judy Zhong, Joshua Chodosh
Adapting the Diabetes Prevention Program for Older Adults: Descriptive Study. JMIR formative research 7 (2023)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Jiyu Kim, Caroline Blaum, Rosie Ferris, Mauricio Arcila-Mesa, Hyungrok Do, Claudia Pulgarin, Johanna Dolle, Jennifer Scherer, Roopa Kalyanaraman Marcello, Judy Zhong
Factors associated with hospital admission and severe outcomes for older patients with COVID-19. Journal of the American Geriatrics Society 70 (7) (2022)
Jennifer S Scherer, Megan E Rau, Anna Krieger, Yuhe Xia, Judy Zhong, Abraham A Brody, David M Charytan, Joshua Chodosh
A Pilot Randomized Controlled Trial of Integrated Palliative Care and Nephrology Care. Kidney360 3 (10) (2022)
Hyungrok Do, Shinjini Nandi, Preston Putzel, Padhraic Smyth, Judy Zhong
A joint fairness model with applications to risk predictions for underrepresented populations. Biometrics (2022)
Hua Zheng, Ilya O Ryzhov, Wei Xie, Judy Zhong
Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records. Drugs 81 (4) (2021)
Nicholas Gulati, Arda B Celen, Paul Johannet, Janice M Mehnert, Jeffrey Weber, Michelle Krogsgaard, Iman Osman, Judy Zhong
Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer medicine 10 (21) (2021)